FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Julia Johansen

Research Profile

Chemicals & Drugs

Concepts & Ideas

Procedures

Disorders

Anatomy

Bone and Bones

Co-author Network

Publications

TOP 3
Marina Harutyunyan; Jørgen Hilden; Gorm Boje Jensen; Julia S Johansen; Christian Gluud; Jens P Gøtze; Jørgen Fischer Hansen; Erik Kjøller; Hans J Kolmos; Per Winkel; Jens Kastrup
Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: A prognostic study within the CLARICOR trial.
Nicolai A Schultz; Jens Werner; Hanni Willenbrock; M Wøjdemann; Nathalia Giese; Thomas Horn; Anne Roslind; Julia S Johansen
MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.
Nicolai A Schultz; Hanni Willenbrock; M Wøjdemann; Klaus K Andersen; Anne Roslind; Julia S Johansen
Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Julia Johansen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marina Harutyunyan; Jørgen Hilden; Gorm Boje Jensen; Julia S Johansen; Christian Gluud; Jens P Gøtze; Jørgen Fischer Hansen; Erik Kjøller; Hans J Kolmos; Per Winkel; Jens Kastrup
Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: A prognostic study within the CLARICOR trial.
Immunobiology 2013;218(7):945-51.
2012: Nicolai A Schultz; Jens Werner; Hanni Willenbrock; M Wøjdemann; Nathalia Giese; Thomas Horn; Anne Roslind; Julia S Johansen
MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2012;25(12):1609-22.
2012: Nicolai A Schultz; Hanni Willenbrock; M Wøjdemann; Klaus K Andersen; Anne Roslind; Julia S Johansen
Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index.
World journal of surgery 2012;36(11):2699-707.
2012: Lise Hoejberg; Julia S Johansen; Lars Bastholt; Ib Jarle Christensen; Julie Gehl; Henrik Schmidt
Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma.
Melanoma research 2012;22(4):287-93.
2012: Nicolai Aagaard Schultz; M Wøjdemann; Mogens Kruhøffer; Lisbeth N Pedersen; Anne Roslind; Flemming Burcharth; Ib J Christensen; Estrid Høgdall; Thomas Horn; Julia S Johansen
Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas.
Pancreas 2012;41(5):759-66.
2012: Marina Harutyunyan; Julia S Johansen; Lars Køber; Christian Torp-Petersen; Michael Christiansen; Jens Kastrup
The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
Immunobiology 2012;217(6):652-6.
2012: Christian B Brøchner; Anne Grete Byskov; Julia S Johansen; Lars A Larsen; Hanne B Mikkelsen; Claus Yding Andersen; Mads Bak; Kjeld Møllgård
YKL-40 is differentially expressed in human embryonic stem cells and in cell progeny of the three germ layers.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2012;60(3):188-204.
2012: Sophine B Krintel; Mikkel Ostergaard; Ehud Schreiber; Assaf Wool; Tomer Zekharya; Pinchas Akiva; Laurent Essioux; Julia S Johansen; Merete L Hetland
CD6 and syntaxin binding protein 6 variants and response to tumor necrosis factor alpha inhibitors in Danish patients with rheumatoid arthritis.
PloS one 2012;7(6):e38539.
2011: Stig E Bojesen; Julia S Johansen; Børge G Nordestgaard
Plasma YKL-40 levels in healthy subjects from the general population.
Clinica chimica acta; international journal of clinical chemistry 2011;412(9-10):709-12.
2011: Naja Dam Mygind; Marina J Harutyunyan; Anders Bruun Mathiasen; Rasmus S Ripa; Jens Jacob Thune; Jens Peter Gøtze; Julia S Johansen; Jens Kastrup
The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease.
Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2011;60(3):281-7.
2011: Mogens K Boisen; Julia S Johansen; Ole Larsen; Benny V Jensen
Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.
Oncology 2011;80(1-2):138-9.
2010: Alisa D Kjaergaard; Stig E Bojesen; Julia S Johansen; Børge G Nordestgaard
Elevated plasma YKL-40 levels and ischemic stroke in the general population.
Annals of neurology 2010;68(5):672-80.
2010: Julia S Johansen; Stig E Bojesen; Anne Tybjaerg-Hansen; Anne K Mylin; Paul A Price; Børge G Nordestgaard
Plasma YKL-40 and total and disease-specific mortality in the general population.
Clinical chemistry 2010;56(10):1580-91.
2010: Redas Trepiakas; Annika Berntsen; Sine Reker Hadrup; Jon Bjørn; Poul F Geertsen; Per thor Straten; Mads Hald Andersen; Anders Elm Pedersen; Amir Soleimani; Torben Lorentzen; Julia S Johansen; Inge Marie Svane
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
Cytotherapy 2010;12(6):721-34.
2010: Benedikte Richter; Anne Roslind; Ulrik Hesse; Jørgen Nordling; Julia S Johansen; Thomas Horn; Alastair Bierre Hansen
YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis.
Histopathology 2010;57(3):371-83.
2009: Julia S Johansen; Stig E Bojesen; Anne K Mylin; Ruth Frikke-Schmidt; Paul A Price; Børge G Nordestgaard
Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):572-8.
2009: Lene Surland Knudsen; Merete Lund Hetland; Julia S Johansen; Henrik Skjødt; Niels Daugaard Peters; Ada Colic; Karin Grau; Hans Jørgen Nielsen; Mikkel Ostergaard
Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy.
Biomarker insights 2009;4():91-5.
2009: Anne Roslind; Julia S Johansen
YKL-40: a novel marker shared by chronic inflammation and oncogenic transformation.
Methods in molecular biology (Clifton, N.J.) 2009;511():159-84.
2008: Anne Roslind; Ann S Knoop; Maj-Britt Jensen; Julia S Johansen; Dorte L Nielsen; Paul A Price; Eva Balslev
YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
Breast cancer research and treatment 2008;112(2):275-85.
2008: Julia S Johansen; Tine Lottenburger; Hans Jørgen Nielsen; Jens Erik B Jensen; Mads N Svendsen; Gine Kollerup; Ib Jarle Christensen
Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(10):2603-8.
2008: Annika Berntsen; Redas Trepiakas; Lynn Wenandy; Poul F Geertsen; Per thor Straten; Mads H Andersen; Anders E Pedersen; Mogens H Claesson; Torben Lorentzen; Julia S Johansen; Inge Marie Svane
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(8):771-80.
2008: Lene S Knudsen; Mette Klarlund; Henrik Skjødt; Trine Jensen; Mikkel Ostergaard; Karl Erik Jensen; Michael S Hansen; Merete L Hetland; Hans J Nielsen; Julia S Johansen
Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
The Journal of rheumatology 2008;35(7):1277-87.
2008: Camilla Nøjgaard; Nis B Høst; Ib Jarle Christensen; Steen Hvitfeldt Poulsen; Kenneth Egstrup; Paul A Price; Julia S Johansen
Serum levels of YKL-40 increases in patients with acute myocardial infarction.
Coronary artery disease 2008;19(4):257-63.
2008: Anne Roslind; Julia S Johansen; Ib Jarle Christensen; Katalin Kiss; Eva Balslev; Dorte Lisbet Nielsen; Jens Bentzen; Paul A Price; Elo Andersen
High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
International journal of cancer. Journal international du cancer 2008;122(4):857-63.
2008: Lene S Knudsen; Ib Jarle Christensen; Tine Lottenburger; Mads N Svendsen; Hans J Nielsen; Lone Nielsen; Kim Hørslev-Petersen; Jens E B Jensen; Gina Kollerup; Julia S Johansen
Pre-analytical and biological variability in circulating interleukin 6 in healthy subjects and patients with rheumatoid arthritis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2008;13(1):59-78.
2008: Merete Lund Hetland; Ib Jarle Christensen; Tine Lottenburger; Julia S Johansen; Mads Nordahl Svendsen; Kim Hørslev-Petersen; Lone Nielsen; Hans Jørgen Nielsen
Circulating VEGF as a biological marker in patients with rheumatoid arthritis? Preanalytical and biological variability in healthy persons and in patients.
Disease markers 2008;24(1):1-10.
2007: Anne Roslind; Julia S Johansen; Nanna Junker; Dorte L Nielsen; Hanife Dzaferi; Paul A Price; Eva Balslev
YKL-40 expression in benign and malignant lesions of the breast: a methodologic study.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2007;15(4):371-81.
2007: Inge Marie Svane; Anders Elm Pedersen; Julia S Johansen; Hans E Johnsen; Dorte Nielsen; Claus Kamby; Svend Ottesen; Eva Balslev; Eva Gaarsdal; Kirsten Nikolajsen; Mogens H Claesson
Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
Cancer immunology, immunotherapy : CII 2007;56(9):1485-99.
2007: Julia S Johansen; Klaus Brasso; Peter Iversen; Børge Teisner; Patrick Garnero; Paul A Price; Ib Jarle Christensen
Changes of biochemical markers of bone turnover and YKL-40 following hormonal treatment for metastatic prostate cancer are related to survival.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3244-9.
2007: Merete Ringsholt; Estrid V S Høgdall; Julia S Johansen; Paul A Price; Lise H Christensen
YKL-40 protein expression in normal adult human tissues--an immunohistochemical study.
Journal of molecular histology 2007;38(1):33-43.
2007: Julia S Johansen; Benny Vittrup Jensen; Anne Roslind; Paul A Price
Is YKL-40 a new therapeutic target in cancer?
Expert opinion on therapeutic targets 2007;11(2):219-34.
2006: L S Knudsen; Mikkel Ostergaard; Bo Baslund; Eva Narvestad; Jørgen Petersen; H J Nielsen; Bo Ejbjerg; Marcin Szkudlarek; Julia S Johansen
Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate.
Scandinavian journal of rheumatology 2006;35(6):489-91.
2006: Bo Gronlund; Estrid V S Høgdall; Ib Jarle Christensen; Julia S Johansen; Bent Nørgaard-Pedersen; Svend A Engelholm; Claus K Høgdall
Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
The International journal of biological markers 2006;21(3):141-8.
2006: Julia S Johansen
Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.
Danish medical bulletin 2006;53(2):172-209.
2006: Klaus Brasso; Ib Jarle Christensen; Julia S Johansen; Børge Teisner; Patrick Garnero; Paul A Price; Peter Iversen
Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma.
The Prostate 2006;66(5):503-13.
2006: Henrik Schmidt; Julia S Johansen; Julie Gehl; Poul F Geertsen; Kirsten Fode; Hans von der Maase
Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
Cancer 2006;106(5):1130-9.
2006: Henrik Schmidt; Julia S Johansen; Pia Sjoegren; Ib Jarle Christensen; Boe Sandahl Sorensen; Kirsten Fode; Jorn Larsen; Hans von der Maase
Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(5):798-804.
2006: Julia S Johansen; Benny Vittrup Jensen; Anne Roslind; Dorte Nielsen; Paul A Price
Serum YKL-40, a new prognostic biomarker in cancer patients?
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(2):194-202.
2005: Mikkel Østergaard; Anne Duer; H Nielsen; Julia S Johansen; Eva Narvestad; Bo Ejbjerg; Bo Baslund; Jakob Møller; Henrik S Thomsen; Jørgen Petersen
Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment.
Annals of the rheumatic diseases 2005;64(10):1503-6.
2005: Claudia Nordenbaek; Julia S Johansen; Poul Halberg; Allan Wiik; Charly Garbarsch; S Ullman; Paul A Price; Steffen Jacobsen
High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
Scandinavian journal of rheumatology 2005;34(4):293-7.
2005: Nanna Junker; Julia S Johansen; Claus B Andersen; Paul E.G. Kristjansen
Expression of YKL-40 by peritumoral macrophages in human small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;48(2):223-31.
2005: Julia S Johansen; Nils Milman; Michael Hansen; Charly Garbarsch; Paul A Price; Niels Graudal
Increased serum YKL-40 in patients with pulmonary sarcoidosis--a potential marker of disease activity?
Respiratory medicine 2005;99(4):396-402.
2005: Nanna Junker; Julia S Johansen; Lasse Tengbjerg Hansen; Eva L Lund; Paul E.G. Kristjansen
Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells.
Cancer science 2005;96(3):183-90.
2003: Benny Vittrup Jensen; Julia S Johansen; Paul A Price
High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(12):4423-34.
2003: Estrid V S Høgdall; Julia S Johansen; Susanne Krüger Kjaer; Paul A Price; Lise Christensen; Jan Blaakaer; Johannes E Bock; Eva Glud; Claus K Høgdall
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival.
Oncology reports 2003;10(5):1535-8.
2003: Camilla Nøjgaard; Julia S Johansen; Erik Christensen; Lene Theil Skovgaard; Paul A Price; Ulrik Becker
Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease.
Journal of hepatology 2003;39(2):179-86.
2003: Camilla Nøjgaard; Julia S Johansen; Henrik Krarup; M Holten-Andersen; A Møller; Flemming Bendtsen
Effect of antiviral therapy on markers of fibrogenesis in patients with chronic hepatitis C.
Scandinavian journal of gastroenterology 2003;38(6):659-65.
2003: Ida Vind; Julia S Johansen; Paul A Price; Pia Munkholm
Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease.
Scandinavian journal of gastroenterology 2003;38(6):599-605.
2003: Hannah Dehn; Estrid V S Høgdall; Julia S Johansen; Morten Jørgensen; Paul A Price; Svend A Engelholm; Claus K Høgdall
Plasma YKL-40, as a prognostic tumor marker in recurrent ovarian cancer.
Acta obstetricia et gynecologica Scandinavica 2003;82(3):287-93.
2002: Christina Cintin; Julia S Johansen; Ib Jarle Christensen; Paul A Price; Susanne Sørensen; Hans Jørgen Nielsen
High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
Cancer 2002;95(2):267-74.
2002: Benny Vittrup Jensen; Julia S Johansen; Torben Skovsgaard; Jette Brandt; Børge Teisner
Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer.
International journal of cancer. Journal international du cancer 2002;98(4):582-9.
2002: Gitte Kronborg; Christian Ostergaard; Nina Weis; Henrik Nielsen; Niels Obel; Svend Stenvang Pedersen; Paul A Price; Julia S Johansen
Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease.
Scandinavian journal of infectious diseases 2002;34(5):323-6.
2001: B Volck; Julia S Johansen; Michael Stoltenberg; Charly Garbarsch; Paul A Price; Mikkel Ostergaard; K Ostergaard; Preben Løvgreen Nielsen; S Sonne-Holm; Ib Lorenzen
Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2001;9(3):203-14.
2001: Julia S Johansen; J R Kirwan; Paul A Price; M Sharif
Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction.
Scandinavian journal of rheumatology 2001;30(5):297-304.
2000: Estrid V S Høgdall; Julia S Johansen; Susanne Krüger Kjaer; Paul A Price; J Blaakjaer; Claus K Høgdall
Stability of YKL-40 concentration in blood samples.
Scandinavian journal of clinical and laboratory investigation 2000;60(4):247-51.
2000: Julia S Johansen; Per Christoffersen; Søren Møller; Paul A Price; Jens H Henriksen; Charly Garbarsch; Flemming Bendtsen
Serum YKL-40 is increased in patients with hepatic fibrosis.
Journal of hepatology 2000;32(6):911-20.
1999: Bo Zerahn; A Kofoed-Enevoldsen; Benny Vittrup Jensen; J Mølvig; Niels E Ebbehøj; Julia S Johansen; Inge-Lis Kanstrup
Pulmonary damage after modest exposure to zinc chloride smoke.
Respiratory medicine 1999;93(12):885-90.
1999: Julia S Johansen; Bo Baslund; Charly Garbarsch; Michael Hansen; Michael Stoltenberg; Ib Lorenzen; Paul A Price
YKL-40 in giant cells and macrophages from patients with giant cell arteritis.
Arthritis and rheumatism 1999;42(12):2624-30.
1999: Julia S Johansen; Michael Stoltenberg; Michael Hansen; Adrian Florescu; Kim Hørslev-Petersen; Ib Lorenzen; Paul A Price
Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity.
Rheumatology (Oxford, England) 1999;38(7):618-26.
1999: Christina Cintin; Julia S Johansen; Ib Jarle Christensen; Paul A Price; Susanne Sørensen; Hans Jørgen Nielsen
Serum YKL-40 and colorectal cancer.
British journal of cancer 1999;79(9-10):1494-9.
1999: B Volck; K Ostergaard; Julia S Johansen; Charly Garbarsch; Paul A Price
The distribution of YKL-40 in osteoarthritic and normal human articular cartilage.
Scandinavian journal of rheumatology 1999;28(3):171-9.
1998: B Volck; Paul A Price; Julia S Johansen; Ole Sørensen; Thomas Benfield; Hans Jørgen Nielsen; J Calafat; Niels Borregaard
YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils.
Proceedings of the Association of American Physicians 1998;110(4):351-60.
1997: Julia S Johansen; Søren Møller; Paul A Price; Flemming Bendtsen; Jette Junge; Charly Garbarsch; Jens H Henriksen
Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis?
Scandinavian journal of gastroenterology 1997;32(6):582-90.
1996: Julia S Johansen; J Hvolris; M Hansen; V Backer; Ib Lorenzen; P A Price
Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint.
British journal of rheumatology 1996;35(6):553-9.
1995: P E Budtz; B C Christoffersen; Julia S Johansen; I Spies; Niels J Willumsen
Tissue kinetics, ion transport, and recruitment of mitochondria-rich cells in the skin of the toad (Bufo bufo) in response to exposure to distilled water.
Cell and tissue research 1995;280(1):65-75.
1995: Julia S Johansen; C Cintin; M Jørgensen; Claus Kamby; P A Price
Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer.
European journal of cancer (Oxford, England : 1990) 1995;31A(9):1437-42.
1992: S Joerring; L T Jensen; G R Andersen; Julia S Johansen
Types I and III procollagen extension peptides in serum respond to fracture in humans.
Archives of orthopaedic and trauma surgery 1992;111(5):265-7.
1991: A Schlemmer; Julia S Johansen; S A Pedersen; J O Jørgensen; C Hassager; Claus Christiansen
The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults.
Clinical endocrinology 1991;35(6):471-6.
1991: D Uebelhart; A Schlemmer; Julia S Johansen; E Gineyts; Claus Christiansen; P D Delmas
Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links.
The Journal of clinical endocrinology and metabolism 1991;72(2):367-73.
1991: C Hassager; L T Jensen; Julia S Johansen; B J Riis; J Melkko; J Pødenphant; Leila Risteli; Claus Christiansen; J Risteli
The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: the effect of nandrolone decanoate and female sex hormones.
Metabolism: clinical and experimental 1991;40(2):205-8.
1991: Julia S Johansen; P D Delmas; B J Riis; E Gineyts; Claus Christiansen
Serum-free gamma carboxyglutamic acid (free Gla) is a poor biochemical marker of bone resorption in early postmenopausal women.
Bone 1991;12(4):257-60.
1990: Julia S Johansen; S B Jensen; B J Riis; Claus Christiansen
Time-dependent variations in bone turnover parameters during 2 months' cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal women.
Metabolism: clinical and experimental 1990;39(11):1122-6.
1990: B Mathiassen; S Nielsen; Julia S Johansen; D Hartwell; J Ditzel; P Rødbro; Claus Christiansen
Long-term bone loss in insulin-dependent diabetic patients with microvascular complications.
The Journal of diabetic complications 1990;4(4):145-9.
1990: Julia S Johansen; S B Jensen; B J Riis; L Rasmussen; M Zachmann; Claus Christiansen
Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy.
The Journal of clinical endocrinology and metabolism 1990;71(1):122-6.
1990: Julia S Johansen; S A Pedersen; J O Jørgensen; B J Riis; Claus Christiansen; J S Christiansen; N E Skakkebaek
Effects of growth hormone (GH) on plasma bone Gla protein in GH-deficient adults.
The Journal of clinical endocrinology and metabolism 1990;70(4):916-9.
1990: B J Riis; Claus Christiansen; Julia S Johansen; J Jacobson
Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
The Journal of clinical endocrinology and metabolism 1990;70(4):920-4.
1989: D Hartwell; Julia S Johansen; Claus Christiansen
Discrepancy between serum concentrations of 1,25-dihydroxyvitamin D metabolites measured by radio-immunoassay and thymus radioreceptor assay during vitamin D2 treatment.
Scandinavian journal of clinical and laboratory investigation 1989;49(6):545-53.
1989: K Overgaard; B J Riis; Claus Christiansen; J Pødenphant; Julia S Johansen
Nasal calcitonin for treatment of established osteoporosis.
Clinical endocrinology 1989;30(4):435-42.
1989: Julia S Johansen; C Hassager; J Pødenphant; B J Riis; D Hartwell; K Thomsen; Claus Christiansen
Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
Bone and mineral 1989;6(1):77-86.
1989: C Hassager; J Pødenphant; B J Riis; Julia S Johansen; J Jensen; Claus Christiansen
Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women.
Metabolism: clinical and experimental 1989;38(3):238-42.
1988: J Pødenphant; B J Riis; Julia S Johansen; A Leth; Claus Christiansen
Iliac crest biopsy in longitudinal therapeutic trials of osteoporosis.
Bone and mineral 1988;5(1):77-87.
1988: Julia S Johansen; B J Riis; C Hassager; M Moen; J Jacobson; Claus Christiansen
The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.
The Journal of clinical endocrinology and metabolism 1988;67(4):701-6.
1988: Julia S Johansen; A Giwercman; D Hartwell; C T Nielsen; P A Price; Claus Christiansen; N E Skakkebaek
Serum bone Gla-protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor I, and serum testosterone.
The Journal of clinical endocrinology and metabolism 1988;67(2):273-8.
1988: Julia S Johansen; B J Riis; P D Delmas; Claus Christiansen
Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women.
European journal of clinical investigation 1988;18(2):191-5.
1988: K Overgaard; L Nilas; Julia S Johansen; Claus Christiansen
Lack of seasonal variation in bone mass and biochemical estimates of bone turnover.
Bone 1988;9(5):285-8.
1987: J Pødenphant; Julia S Johansen; K Thomsen; B J Riis; A Leth; Claus Christiansen
Bone turnover in spinal osteoporosis.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1987;2(6):497-503.
1987: K Thomsen; B J Riis; Julia S Johansen; Claus Christiansen; P Rødbro
Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 1987;1(2):169-75.
1987: D Hartwell; B J Riis; Claus Christiansen; K Thomsen; Julia S Johansen; P Rødbro
Bone metabolism and bone status in osteoporotic patients.
Acta medica Scandinavica 1987;222(5):453-8.